A5043086563- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Neuroblastoma Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Protein Degradation and Inhibitors
- Palliative Care and End-of-Life Issues
- PARP inhibition in cancer therapy
- Histiocytic Disorders and Treatments
- Gestational Trophoblastic Disease Studies
- Phagocytosis and Immune Regulation
- Cancer-related molecular mechanisms research
- Ethics in Clinical Research
- Multiple Myeloma Research and Treatments
- Patient Dignity and Privacy
- Patient Satisfaction in Healthcare
- Renal and related cancers
- Cancer Treatment and Pharmacology
Mayo Clinic in Florida
2014-2025
Jacksonville College
2014-2024
WinnMed
2014-2024
University of Missouri–Kansas City
2023
Florida Cancer Specialists & Research Institute
2015
Mayo Clinic
2013
Clinical trials reporting the robust antitumor activity of immune checkpoint inhibitors (ICIs) in microsatellite instability-high (MSI-H) solid tumors have used tissue-based testing to determine MSI-H status. This study assessed if detected by a plasma-based circulating tumor DNA liquid biopsy test predicts response ICI patients with pancreatic ductal adenocarcinoma (PDAC). Retrospective analysis PDAC and identified on Guardant360 from October 2018 April 2021 was performed; clinical outcomes...
PURPOSE Pancreatic cancer (PC) carries a poor prognosis with high rates of unresectable/metastatic disease at diagnosis, recurrence after resection, and few systemic therapy options. Deficient mismatch repair (dMMR)/high microsatellite instability (MSI-H) PCs demonstrated uncharacteristically outcomes in KEYNOTE-158, evaluating pembrolizumab MSI-H solid tumors. Our study aggregates the Mayo Clinic experience dMMR/MSI-H PCs, characterizing clinical, molecular, treatment response patterns...
PURPOSE Pancreatic acinar cell carcinoma (PACC) is a rare and aggressive form of pancreatic cancer that originates in the cells exocrine pancreas. In this study, we aimed to investigate clinical molecular characteristics patients with PACC at our institution. METHODS This was retrospective study seen Mayo Clinic between 2002 2023. Baseline patient characteristics, tumor pathology, treatment strategies used, survival outcomes were analyzed. Kaplan-Meier curves estimated using newsurv macros...
Background: Patients with biliary tract cancer (BTC) have a dismal prognosis and limited treatment options. Given the potential for immunotherapy in patients BTC, we studied expression of programmed death ligand-1 (PD-L1)/programmed death-1 (PD-1) evaluated associated genetic alterations BTC. Methods: By immunohistochemistry (IHC), PD-L1 (SP142 antibody; ≥2+ and/or ≥5% staining on tumor cells considered positive) PD-1 [NAT105 ≥1+ infiltrating lymphocytes (TILs) positive] was next-generation...
PURPOSE Guidelines recommend germline genetic testing (GT) for patients with pancreatic ductal adenocarcinoma (PDAC). This study aims to evaluate the utilization and outcomes of multigene panel GT in PDAC. METHODS retrospective, multisite included PDAC diagnosed between May 2018 August 2020 at Mayo Clinic Arizona, Florida, Minnesota. Discussion, uptake, were compared before (May 1, 2018-May 2019) after (August 2019-August 2020) guideline update, accounting a transition period. RESULTS The...
Recent advances in molecular diagnostic technologies allow for the evaluation of solid tumor malignancies through noninvasive blood sampling, including circulating DNA profiling (ctDNA). Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, often because late presentation disease. Diagnosis is made using endoscopic ultrasound or retrograde cholangiopancreatography, which does not yield enough tissue next-generation sequencing. With this study, we sought to characterize ctDNA genomic...
MSI-H identified by ctDNA: prevalence across 21 advanced cancers and outcomes from >700 patients.
727 Background: PARP inhibition (PARPi) is a standard maintenance therapy for patients (pts) with germline BRCA1/2 mutations in pancreatic cancer. Combination of PARPi and immunotherapy has potential to increase efficacy may offer benefit beyond . Methods: We performed multisite single-arm phase 2 study using the highly potent niraparib anti-PD1 drug dostarlimab pts or somatic HRD BRCA1/2, PALB2, RAD51C/D, BARD1 Pts were required have metastasis, progressed on ≥1 regimen, prior...
This study investigated the burden of comorbidities and concomitant non-cancer medications their cost in patients with neuroendocrine tumors (NETs). Adults gastroenteropancreatic (GEP)-NETs lung-NETs, or without carcinoid syndrome (CS), who initiated first-line NET treatment (index date) a somatostatin analog telotristat had ≥ 1 inpatient 2 distinct outpatient claims (study period January 1, 2016–December 31, 2022) were identified from US MarketScan database matched (age, sex, insurance...
Abstract BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a rare but aggressive cancer with limited curative options outside of surgical resection. Trans-arterial radioembolization (TARE) yttrium-90 promising treatment retrospective data showing an overall survival (OS) up to 30 months. The single arm prospective MISHPEC trial combined TARE gemcitabine and cisplatin showed response rate (ORR) 39% at 3 months along median OS 22 PDL1 inhibitor (Durvalumab) has shown modest benefit in...
This investigation sought to evaluate the prognostic value of pretreatment circulating tumor DNA (ctDNA) in metastatic biliary tract cancers (BTCs) treated with platinum-based first-line chemotherapy treatment.
PURPOSE This phase II study evaluated the efficacy and tolerability of onvansertib, a polo-like kinase 1 (PLK1) inhibitor, in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI) + bevacizumab for second-line treatment KRAS -mutant metastatic colorectal cancer (mCRC). PATIENTS AND METHODS multicenter, open-label, single-arm enrolled patients -mutated mCRC previously treated oxaliplatin fluorouracil or without bevacizumab. Patients received onvansertib (15 mg/m 2 once daily on days...
Through our involvement in KEYNOTE-059, we unexpectedly observed durable responses two patients with metastatic gastroesophageal adenocarcinoma (mGEA) who received ramucirumab (anti-VEGFR-2)/paclitaxel after immune checkpoint inhibition (ICI). To assess the reproducibility of this observation, piloted an approach to administer ramucirumab/paclitaxel ICI more patients, and explored changes microenvironment. Nineteen consecutive mGEA followed by ramucirumab/paclitaxel. Most (95%) did not...
Plasma-based circulating cell-free tumor DNA (ctDNA) genomic profiling by next-generation sequencing (NGS)is an emerging diagnostic tool for pancreatic cancer (PC). The impact of detected alterations and variant allele fraction (VAF) in response to systemic treatments outcomes is under investigation.Patients with advanced PC who had ctDNA profiled at time initial diagnosis were retrospectively evaluated. We considered the somatic alteration highest VAF as dominant clone frequency (DCAF). NGS...
PURPOSE Thrombocytopenia is a relatively common dose-limiting toxicity during peptide receptor radionuclide therapy (PRRT) in patients with NET. Although uncommon, some develop persistent cytopenia and eventually therapy-related myeloid neoplasm (t-MN), which has dismal prognosis. As the indications for PRRT are expanding, it important to investigate factors that may predict cytopenias during/after PRRT. We prospectively evaluated prevalence of clonal hematopoiesis (CH) NET undergoing...
The aim of the current study was to describe risk hepatotoxicity for patients with gastroenteropancreatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy (PRRT) a very high liver tumor burden, defined as involving more than 75% liver. Methods: We conducted retrospective analysis 371 who received at least 1 cycle 177Lu-DOTATATE Mayo Clinic advanced tumors. identified 15 total involvement on 68Ga-DOTATATE PET/CT and either contrast-enhanced abdominal MRI or dual-phase CT...
592 Background: The introduction of peptide receptor radionuclide therapy (PRRT) using Lutetium-177 ( 177 Lu) DOTATATE has led to a paradigm shift in the treatment neuroendocrine tumors (NETs). Hematological toxicity is well-recognized adverse effect (AE) Lu DOTATATE. Most cytopenias are transient, with an estimated incidence 10-25%, typically mild moderate severity (grade G1-2). most dreaded AE PRRT therapy-related myeloid neoplasm (t-MN), 2-8% and higher reported patients who also received...
We previously reported an extremely rare case of follicular dendritic cell sarcoma (FDCS) presented as a thyroid mass. Given the rarity this disease, there are no personalized and molecularly targeted treatment options due to lack knowledge in genomic makeup tumor. A 44-year-old white woman was diagnosed with extranodal FDCS thyroid. The patient underwent total thyroidectomy, central compartment dissection, parathyroid re-implantation, adjuvant radiation therapy. Tumor DNA sequencing 236...
Background: Pancreatic adenocarcinoma remains one of the most lethal malignancies with little treatment advancements. Other less common pancreatic cancer histologies have different outcomes and disease course. In this article, we report two cases rare tumors. Presentation: The first case is a 59-year old, who was undergoing surveillance known cyst, which eventually enlarged. mass resected pathology revealed undifferentiated carcinoma osteoclast-like giant cells. patient did not receive any...
Studies have shown that the albumin-bilirubin (ALBI) grade can be a superior prognosticator for patients undergoing Yttrium-90 (Y90) glass microsphere radioembolization hepatocellular carcinoma (HCC) compared to Child-Pugh (CP) scoring system. Less is known about applicability of this score in non-hepatocellular malignancies using Y90 resin microspheres. This study evaluates ALBI grade's ability predict overall survival and biochemical toxicity body surface area dosimetry (BSA) primary...